Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
HPV Type 6 L1 Protein, Quantity: 20 microgram; HPV Type 11 L1 Protein, Quantity: 40 microgram; HPV Type 16 L1 Protein, Quantity: 40 microgram; HPV Type 18 L1 Protein, Quantity: 20 microgram
Merck Sharp & Dohme (Australia) Pty Ltd
HPV Type 11 L1 Protein,HPV Type 16 L1 Protein,HPV Type 18 L1 Protein,HPV Type 6 L1 Protein
Injection, suspension
Excipient Ingredients: aluminium; histidine; polysorbate 80; borax; water for injections; sodium chloride
Intramuscular
10 x 0.5mL vials, 1 x 0.5mL vial
(S4) Prescription Only Medicine
GARDASIL is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18 (which are included in the vaccine). GARDASIL is indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by HPV types 6, 11, 16, and 18 (which are included in the vaccine). *Immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.
Visual Identification: Cloudy white liquid; Container Type: Vial; Container Material: Glass; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Licence status A
2006-06-22
PRODUCT INFORMATION GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant vaccine] DESCRIPTION GARDASIL ® is a recombinant, quadrivalent vaccine. The quadrivalent Human Papillomavirus Virus-Like Particle vaccine (HPV VLP vaccine) is a sterile liquid suspension prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, and 18. The L1 proteins are produced by separate fermentations in recombinant yeast _Saccharomyces _ _cerevisiae_ CANADE 3C-5 (Strain 1895) and self-assembled into VLPs. The VLPs for each type are purified and adsorbed on aluminium-containing adjuvant (amorphous aluminium hydroxyphosphate sulfate, or AAHS). The quadrivalent HPV VLP vaccine is prepared by combining the adsorbed VLPs of each HPV type, the aluminium-containing adjuvant formulation, and a buffer. GARDASIL is a sterile preparation for intramuscular administration. Each 0.5-mL dose contains approximately 20 mcg of HPV 6 L1 protein, 40 mcg of HPV 11 L1 protein, 40 mcg of HPV 16 L1 protein, and 20 mcg of HPV 18 L1 protein. Each 0.5-mL dose of the vaccine contains approximately 225 mcg of aluminium (as amorphous aluminium hydroxyphosphate sulfate adjuvant), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of polysorbate 80, 35 mcg of borax, residual traces (<7mcg/dose) of yeast protein and water for injection. The product does not contain a preservative or antibiotics. PHARMACOLOGY MECHANISM OF ACTION GARDASIL contains HPV 6, 11, 16 and 18 L1 VLPs. Each VLP is composed of a unique recombinant L1 major capsid protein for the respective HPV type. Because the virus-like particles contain no viral DNA, they cannot infect cells or reproduce. Pre-clinical data suggests that the efficacy of L1 VLP vaccines is mediated by the development of humoral immune responses. Induction of anti-papillomavirus antibodies with L1 VLP vaccines resulted in protection against infection. Administration of serum from vaccinated to unvaccinated animals resulted Read the complete document